1	Performance of the TaqMan™ COVID-19 Pooling Kit for detection of SARS-CoV-2 in Asymptomatic and
2	Symptomatic populations at an Institution of Higher Education
3	
4	Troy Ganz <sup>a</sup> , Sarah Sanderson <sup>a</sup> , Connor Baush <sup>a</sup> , Melanie Mejia <sup>a</sup> , Manoj Gandhi <sup>b</sup> , Jared Auclair <sup>a#</sup> .
5	
6	<sup>a.</sup> Life Science Testing Center, Northeastern University, Burlington, MA, USA
7	<sup>b.</sup> Thermo Fisher Scientific, South San Francisco, CA, USA
8	
9	Running Head: RT-qPCR Sensitivity for Pooled Asymptomatic Sars-CoV-2
10	
11	Address correspondence to Jared Auclair, Ph.D., j.auclair@northeastern.edu

## 12 Abstract:

13 Clinical evidence for asymptomatic cases of coronavirus disease (COVID-19) has reinforced the 14 significance of effective surveillance testing programs. Quantitative reverse transcriptase polymerase 15 chain reaction (RT-qPCR) assays are considered the 'gold standard' for detection of severe acute 16 respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA. However, the labor and resource requirements 17 can be prohibitive with respect to large testing volumes associated with the pandemic. Pooled testing 18 algorithms may serve to increase testing capacity with more efficient resource utilization. Due to the 19 lack of carefully curated cohorts, there is limited evidence for the applicability of RT-PCR pooling in 20 asymptomatic COVID-19 cases. In this study, we compared the analytical sensitivity of the TaqMan™ 21 SARS-CoV-2 Pooling Assay to detect one positive sample in a pool of five anterior nare swabs in 22 symptomatic and asymptomatic cohorts at an institute of higher education. Positive pools were 23 deconvoluted and each individual sample was retested using the TagPath<sup>™</sup> COVID-19 Combo Kit. Both 24 assays target the open reading frame (ORF) 1ab, nucleocapsid (N), and spike (S) gene of the strain that 25 originated in Wuhan, Hubei, China. Qualitative results demonstrated absolute agreement between pooled and deconvoluted samples in both cohorts. Independent t-test performed on Ct shifts confirmed 26 27 an insignificant difference between cohorts with p-values of 0.306 (Orf1ab), 0.147 (N), and 0.052 (S). All 28 negative pools were correctly reported as negative. Thus, pooled PCR testing up to five samples is a valid 29 method for surveillance testing of students and staff in a university setting, especially when the 30 prevalence is expected to be low.

## 31 Introduction:

32	Efforts to mitigate the reproductive number ( $R_0$ ) for the coronavirus disease 2019 (COVID-19) pandemic,
33	an emergent respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-
34	CoV-2), has been undermined by the potential for sustained transmission through pre-symptomatic,
35	paucisymptomatic (subclinical), and asymptomatic carriers [1]. Growing evidence from immunological
36	case studies and bioinformatic investigations have substantiated clinical diagnostic testing that have
37	reported insignificant variance in results among patients that differ in symptomology. Asymptomatic
38	patients have reportedly developed ground-glass opacities in lung tissue and significant adaptive
39	immune (IgG and IgM) responses, however cell-mediated immune response from asymptomatic cases
40	have shown to be less significant compared to symptomatic cases [2,3]. A recent investigation noted a
41	correlation between globally reported asymptomatic cases and a single nucleotide polymorphism (SNP)
42	in SARS-CoV-2 RNA at position 11083G>T translating to a phenylalanine mutation (L37F) on non-
43	structural protein 6 (NSP6) [4]. While a less severe immune response may be elicited in asymptomatic
44	cases, the replication mechanisms in these individuals remain intact, and this necessitates effective risk
45	management measures [5].
46	The analytical sensitivity of RT-qPCR has propelled its utility as the 'gold standard' to accurately detect
47	SARS-CoV-2 RNA from upper respiratory specimens (e.g., nasopharyngeal, anterior nare, and saliva);
48	however, the high-complexity format has merged with demands of a pandemic to generate severe
49	shortages in materials and technical personnel. A resurgence of interest in group testing, or sample
50	pooling, whereby the ratio of specimens to result is greater than one, has led investigators to optimize
51	protocols that would allow an increase in testing capacity without requiring additional resources [6].
52	Caveats include a linear loss of sensitivity with sample dilution, and, in hierarchical systems, disease
53	prevalence may determine efficiency as positive pools are deconvoluted to retest each patient

54 individually [7]. Nevertheless, sample pooling stands to provide an accurate and affordable method for

55 general population testing.

56 Since gaining USFDA emergency use authorization (EUA) for the TaqPath<sup>™</sup> COVID-19 Combo Kit on

- 57 March 24, 2020, Thermo Fisher Scientific, Inc. has developed a specialized RT-qPCR testing kit with
- 58 enhanced sensitivity for the purposes of pooling up to five samples known as the TaqMan<sup>™</sup> SARS-CoV-2
- 59 Pooling Assay. In the following study, we compared the sensitivity of the TaqMan<sup>™</sup> assay to detect one
- 60 positive sample in a pool of five from 30 symptomatic and 30 asymptomatic individuals that were
- 61 previously characterized as positive using the TaqPath<sup>™</sup> COVID-19 Combo Kit; 10 negative pools of five
- 62 were included as a control group.
- 63 Methods:

## 64 Sample Collection, Storage, and Preanalytical Processing:

65 The study was conducted at the Northeastern University COVID-19 response laboratory, the Life Science 66 Testing Center (LSTC; Burlington, MA, USA), which performs population testing for university affiliates. 67 Students on campus are required to test every three days while staff and faculty on campus test twice a 68 week. Affiliates attending campus are required to complete a daily wellness tracker, or a two-question 69 survey, that identifies whether they have experienced COVID-19 related symptoms or have been in close 70 contact with a positive COVID-19 case in the past 24 hours. Depending on the survey results, they are 71 directed to get tested at either the non-symptomatic site (Cabot Center), where observed self-collection 72 is performed, or the symptomatic site (Marino Center), where collection is performed by a healthcare 73 professional. Temperature checks and general symptom screening were performed by trained personnel 74 on the subjects at both sites to determine presence or absence of symptoms. Anterior nasal swabs (polyester) are collected in 3 mL BD Vacutainer<sup>®</sup> (without additive) tubes and transported dry to the 75 76 LSTC facility. Upon logging into the laboratory information system (LIMS), 3 mL of viral transport media 77 (VTM; Redoxica, Little Rock, AR, USA) is added and the sample is shaken at 1000 rpm for 5 minutes.

78	Processed specimens are stable for <72 hours at 2-8°C. Positive samples are catalogued, split into three
79	aliquots, and stored indefinitely at -80°C. Depending on the site at which the samples are collected
80	(Cabot or Marino), this monitoring approach allows for curated cohorts of symptomatic or
81	asymptomatic cases.
82	TaqMan™ SARS-CoV-2 Pooling Assay: Pooled Specimen RNA Extraction and RT-qPCR Setup
83	Pools consisting of five samples were constructed from one positive sample and four negative samples.
84	Positive samples were selected at random from -80°C storage and thawed at 2-8°C. RNA extraction was
85	performed using 400 μL of combined sample volume using the MagMAX™ Viral/Pathogen II (MVP II)
86	Nucleic Acid Isolation Kit (Thermo Fisher Scientific, Waltham, MA, USA) by combining 10 $\mu$ L of
87	Proteinase K, 80 μL of each sample (400 μl pooled volume), 550 μL of lysis buffer with RNA binding
88	beads, and 10 $\mu L$ of MS2 phage extraction control to a single well of an Agilent 1 mL 96-well plate. The
89	plate was vortexed 2 minutes at 1050 rpm, incubated 5 minutes at 65°C, vortexed for 5 minutes at 1050
90	rpm, and incubated at room temperature on a magnetic stand. After waste aspiration, the beads
91	underwent three cycles of resuspension/aspiration in 1 mL wash buffer, 1 mL 80% ethanol, and 50 $\mu$ L
92	elution buffer, respectively. RT-qPCR was performed using 17.5 $\mu$ L of eluant added to 7.5 $\mu$ L of reaction
93	mix that contained 6.25 μL TaqPath™ 1-Step RT-qPCR MM, CG (4X) and 1.25 μL TaqMan™ SARS-CoV-2
94	Pooling Multiplex Assay.
95	TaqPath™ COVID-19 Combo Kit: Deconvoluted Specimen RNA Extraction and RT-qPCR Setup
96	Pools that tested positive were deconvoluted and each of the five component specimens were repeated
97	using the TaqPath™ COVID-19 Combo Kit currently employed at the LSTC. Briefly, RNA extraction was
98	performed using the MVPII kit with 5 $\mu$ L of Proteinase K, 200 $\mu$ L sample, 275 $\mu$ L lysis buffer with RNA
99	binding beads, and 5 $\mu$ L MS2 phage extraction control. Wash procedure was performed using an Agilent
100	Bravo liquid handler (Agilent Technologies, Santa Clara, CA, USA) whereby, after initial shaking 2 minutes

101 at 1050 rpm and 5 minutes incubation at 65°C, the beads underwent three cycles of

- resuspension/aspiration in 165 μL wash buffer, 165 μL 80% ethanol, and 50 μL elution buffer,
- respectively. RT-qPCR was performed using 10 µL of eluate added to 15 µL of reaction mix that
- 104 contained 6.25 µL TaqPath<sup>™</sup> 1-Step Multiplex Master Mix (No ROX<sup>™</sup>) (4x), 1.25 µL COVID-19 Real Time
- 105 PCR Assay Multiplex, and 7.5 μL Nuclease-free water.
- 106 RT-qPCR Thermal Profile and Results Management
- 107 Both, the TaqMan<sup>™</sup> and TaqPath<sup>™</sup>, methods contain primers and probes that target the SARS-CoV-2
- 108 open reading frame (ORF) 1ab, nucleocapsid (N), and spike (S) genes as well as the MS2 phage
- 109 extraction control (reporter dyes FAM, VIC, ABY, and JUN, respectively). Thermal profile parameters for
- both assays involved a 2-minute UNG incubation cycle at 25°C, a 10-minute reverse transcriptase
- incubation cycle at 53°C, a 2-minute activation cycle at 95°C, and 40 cycles of a 3-second denaturation at
- 112 95°C followed by 30-second anneal/extension cycle at 60°C on Applied Biosystems<sup>™</sup> 7500 Fast Dx Real-
- 113 Time PCR Instrument (Thermo Fisher Scientific, Waltham, MA, USA). Resulting threshold cycle (Ct) values
- 114 were extracted using COVID-19 Interpretive Software and analyzed using Microsoft Excel<sup>®</sup> and
- 115 GraphPad Prism version 9 for Windows (GraphPad Software, San Diego, CA, USA). Qualitative endpoints
- set to determine target presence were  $C_t \leq 37$  for SARS-CoV-2 genes and  $C_t \leq 32$  for MS2 control;  $\geq 2/3$
- 117 SARS-CoV-2 genes designated a positive result and 1/3 SARS-CoV-2 genes designated an indeterminate

118 result.

119 Results:

Average monthly prevalence estimates ranging August 2020 to April 2021 for the Cabot Center (nonsymptomatic) was 0.159% (CI.95 0.086-0.234%) and Marino Center (symptomatic) was 3.33% (CI.95 2.05-4.61%). Thirty samples from each of the two sites were used to generate 60 five-sample pools with 240 negative samples. Each of the 60 five-sample pools tested positive using the TaqMan<sup>™</sup> pooling method and statistical analysis was performed using the deconvoluted result. Average C<sub>t</sub> values for the pooled asymptomatic samples were 22.17 (CI.95 20.18-24.16), 22.66 (CI.95 20.76-24.57), and 23.15


126	(CI.95 21.13-25.17) and the deconvoluted asymptomatic samples were 20.64 (CI.95 18.59-22.68), 21.30
127	(CI.95 19.38-23.22), and 20.81 (CI.95 18.92-22.69) for the ORF1ab, N, and S genes, respectively (Figure1:
128	a, b, c). Average C <sub>t</sub> values for the pooled symptomatic samples were 22.47 (CI.95 20.31-24.63), 23.31
129	(CI.95 21.19-25.44), and 24.01 (CI.95 21.15-26.87) and the deconvoluted symptomatic samples were
130	20.65 (CI.95 18.53-22.77), 21.70 (CI.95 19.60-23.80), and 21.17 (CI.95 18.63-23.71) for the ORF1ab, N,
131	and S genes, respectively (Figure1: d, e, f). Dependent t-test analysis comparing pooled to deconvoluted
132	data sets indicated a statistically significant difference with p-values of <0.001 for all comparisons,
133	however this is reflective of the expected effect on $C_t$ value due to dilution. Average $C_t$ shifts of
134	1.54±1.07 (ORF1ab), 1.37±0.77 (N), and 2.34±1.68 (S) for the asymptomatic cohort and 1.82±1.01
135	(ORF1ab), 1.62±0.48 (N), and 3.10±1.37 (S) for the symptomatic cohort was observed. Independent t-
136	test did not show a statistically significant $C_t$ shift between the asymptomatic and symptomatic cohorts
137	with p-values of 0.306, 0.147, and 0.052 for ORF1ab, N, and S genes, respectively (Figure 1g). Each
138	negative pool reported negative and were not deconvoluted.
139	Discussion:
140	This study sought to confirm SARS-CoV-2 infections that cause mild immune responses proliferate to
141	similar extents as those that elicit severe cases of COVID-19, which enables equal probability of
142	detection in RT-qPCR assay. Furthermore, the TaqMan™ multiplex assay identified each positive sample
143	in pools of five with minimal loss of sensitivity. Prevalence of SARS-CoV-2 variants, apparent by S gene
144	target loss, has increased by an order of magnitude since November 2020 at the LSTC and cases
145	represented 7% of asymptomatic and 20% of symptomatic cases in the sample size for this study [8]. It is
146	important to note, significant dilution effects observed in all genes was a result of interpreting one
147	positive per pool of five and may indicate a limitation of the experimental design due to probability of
148	more than one positive per pool in practice [9]. Thus, the practical significance observed by the average

- 149 Ct shifts and negligible impact to qualitative agreement supports retention of RT-qPCR sensitivity at a
- 150 minimum.
- 151 This strategy of increased extraction and elution volumes for group tests reported absolute qualitative
- agreement to the deconvoluted counterpart, including a 1/3 gene positive case, and produced a more
- 153 conserved C<sub>t</sub> shift [7,9]. Since symptomatic subjects tend to have a significantly higher prevalence of
- 154 COVID-19 in a pandemic setting, from a resource efficiency standpoint, it is advisable to consider pooling
- samples when testing subjects who are non-symptomatic such as in vaccinated populations, where the
- 156 prevalence rates are expected to be significantly lower.
- 157 Ethical Statement:
- 158 This work was performed under Northeastern University Office of Human Subject Research Protection
- 159 (HSRP) IRB approval.
- 160 **Conflicts of Interest**:
- 161 The authors declare no conflict of interest.
- 162 Acknowledgements:
- 163 The authors would like to acknowledge the efforts of the LSTC technical staff, including M.K., R.M. who
- 164 made contributions to this work.

## 165 References:

- 166 1. Fiore VG. DeFelice N. Glicksberg BS. Perl O. Shuster A. Kulkarni K. O'Brien M. Pisauro MA. Chung 167 D, Gu X. 2021. Containment of COVID-19: Simulating the impact of different policies and testing 168 capacities for contact tracing, testing, and isolation. PLoS One 16:e0247614. 169 doi:10.1371/journal.pone.0247614 170 2. Long QX, Jia YJ, Wang X, Deng HJ, Cao XX, Yuan J, Fang L, Cheng XR, Luo C, He AR, Tang XJ, Hu JL, 171 Hu Y, Tang N, Cai XF, Wang DQ, Hu J, Qiu JF, Liu BZ, Chen J, Huang AL. 2021. Immune memory in 172 convalescent patients with asymptomatic or mild COVID-19. Cell Discov 7:18 3. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K, Zhang F, Gong J, 173 174 Wu B, Liu XM, Li JJ, Qiu JF, Chen J, Huang AL. 2020. Clinical and immunological assessment of 175 asymptomatic SARS-CoV-2 infections. Nat Med 26:1200-1204 176 4. Wang R, Chen J, Hozumi Y, Yin C, Wei GW. 2020. Decoding Asymptomatic COVID-19 Infection 177 and Transmission. J Phys Chem Lett 11:10007-10015. 178 5. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, Ladhani S, Zambon M, Gopal R. 2020. Duration of infectiousness and correlation with RT-PCR cycle threshold values in 179 cases of COVID-19, England, January to May 2020. Euro Surveill 25. 180 6. Praharaj I, Jain A, Singh M, Balakrishnan A, Dhodapkar R, Borkakoty B, Ashok M, Das P, Biswas D, 181 182 Kalawat U, Turuk J, Sugunan AP, Prakash S, Singh AK, Barathidasan R, Subhadra S, Sabat J, 183 Manjunath MJ, Kanta P, Mudhigeti N, Hazarika R, Mishra H, Abhishek K, Santhalembi C, Dikhit 184 MR, Vijay N, Narayan J, Kaur H, Giri S, Gupta N. 2020. Pooled testing for COVID-19 diagnosis by real-time RT-PCR: A multi-site comparative evaluation of 5- & 10-sample pooling. Indian J Med 185 186 Res 152:88-94. 187 7. Abdalhamid B, Bilder CR, Garrett JL, Iwen PC. 2020. Cost Effectiveness of Sample Pooling to Test
- 188 for SARS-CoV-2. J Infect Dev Ctries 14:1136-1137.

189	8.	Bal A, Destras G, Gaymard A, Stefic K, Marlet J, Eymieux S, Regue H, Semanas Q, d'Aubarede C,
190		Billaud G, Laurent F, Gonzalez C, Mekki Y, Valette M, Bouscambert M, Gaudy-Graffin C, Lina B,
191		Morfin F, Josset L, Group CO-DHS. 2021. Two-step strategy for the identification of SARS-CoV-2
192		variant of concern 202012/01 and other variants with spike deletion H69-V70, France, August to
193		December 2020. Euro Surveill 26.
194	9.	Alcoba-Florez J, Gil-Campesino H, García-Martínez de Artola D, Díez-Gil O, Valenzuela-Fernández
195		A, González-Montelongo R, Ciuffreda L, Flores C. 2021. Increasing SARS-CoV-2 RT-qPCR testing
196		capacity by sample pooling. Int J Infect Dis 103:19-22.






Figure 1: Pairwise comparisons of pooled and deconvoluted samples for each gene target (ORF1ab, N, and S) from Asymptomatic (a,b,c) and Symptomatic cohorts (d,e,f); means indicated by dashed intersects. Boxand-whisker plot describing C<sub>t</sub> shift for each gene from each cohort; bars are CI.95; ranges marked; pvalues annotated (g).